


Supplementary Figure S10. Kaplan-Meier analysis of OS for (A) the tTMB <10 mut/Mb subgroup and (B) the tTMB ≥10 mut/Mb subgroup. CI, confidence interval; D, durvalumab; EP, platinum-etoposide; HR, hazard ratio; OS, overall survival; T, tremelimumab; tTMB, tissue tumor mutational burden.


A



Number of patients at risk

D+EP	50	47	38	30	26	19	13	12	8	6	4	1	0
D+T+EP	57	52	41	28	18	14	14	12	11	7	1	0	0
EP	45	41	36	23	14	13	12	7	3	0	0	0	0

B



Number of patients at risk

D+EP	57	54	48	35	26	20	16	14	9	2	0	0	0
D+T+EP	48	43	36	28	20	16	16	13	9	3	1	0	0
EP	26	22	20	17	10	7	4	3	1	0	0	0	0